Psoriatic arthritis

Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients

Milena L Pachowsky, Maria Gabriella Raimondo, Cong Xu, Simon Rauber, Koray Tascilar, Hannah Labinsky, Mario Vogg, Mina Saad Aziz Saad, David Simon, Juergen Rech, Alina Soare, Lars Braeuer, Arnd Kleyer, Georg Schett, Andreas Ramming

10.1136/annrheumdis-2021-222061

April 22, 2022

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

Atul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester

10.1136/annrheumdis-2021-222027

April 7, 2022

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee

10.1136/annrheumdis-2021-221664

March 3, 2022

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Elke Theander, Josef S Smolen

10.1136/annrheumdis-2021-221640

February 24, 2022

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Frank Behrens

10.1136/annrheumdis-2021-221019

December 15, 2021

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis

Sayam Dubash, Oras A Alabas, Xabier Michelena, Leticia Garcia-Montoya, Richard J Wakefield, Philip S Helliwell, Paul Emery, Dennis G McGonagle, Ai Lyn Tan, Helena Marzo-Ortega

10.1136/annrheumdis-2021-220964

December 10, 2021

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes

10.1136/annrheumdis-2021-220991

November 24, 2021

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz

10.1136/annrheumdis-2021-221048

November 23, 2021

Does biologic therapy impact the development of PsA among patients with psoriasis?

Elana Meer, Joseph F Merola, Robert Fitzsimmons, Thorvardur Jon Love, Shiyu Wang, Daniel Shin, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Jose U Scher, C T Ritchlin, Joel M Gelfand, Alexis Ogdie

10.1136/annrheumdis-2021-220761

October 6, 2021

Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis

Maria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R Soriano

10.1136/annrheumdis-2021-220865

July 19, 2021